Create a narrative

UroGen Pharma Community

NasdaqGM:URGN Community

1 Narratives written by author
0 Comments on narratives written by author
6 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 7 Analysts

UGN-102 Approval Will Broaden Bladder Cancer Treatment Options

Key Takeaways Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power. Expanding the sales team and strong R&D alignment with FDA signal proactive strategies for revenue growth and diversified long-term earnings.

US$34.00

FV

70.2% undervalued

67.08%

Revenue growth p.a.

0

0

0

New